Daklanork (Daclatasvir 60mg) is a new direct-acting antiviral drug that targets different steps of the hepatitis C virus (HCV) lifecycle.

Daklanork should be combined with other medications, which may include other direct-acting antivirals that work differently. Indicated for use by adults with chronic Hepatitis C, meaning infection lasting more than six months. It is approved for people with HCV genotype 1, 2, 3 or 4.

Daklanork may work for some people better than for others. Several factors are responsible for the response: HCV genotype, extent of liver damage and previous treatment history. People with liver cirrhosis do not respond as well as those with mild or moderate liver fibrosis. Depending on which drugs Daklanork is combined with, people who are new to treatment may have a better chance of being cured.

Daklanork is available in 60mg tablets, and the usual dose is once daily with or without food. It must be used in combination with other hepatitis C medications and is not effective if taken alone. Treatment should be managed by a healthcare provider who has experience treating hepatitis C.

Combined with Length of treatment
Genotype 1 Daklanork & Sofolanork 12 weeks (no cirrhosis)

24 weeks (with cirrhosis)

Genotype 2 Daklanork & Sofolanork No recommendation regarding which patients with
genotype 2 HCV are eligible for treatment with daclatasvir due to limited
Genotype 3 Daklanork & Sofolanork & Ribavirin 24 weeks (with cirrhosis or treatment-experienced)
Genotype 4 Daklanork & Sofolanork


Daklanork & Pegylated Interferon &

12 weeks (no cirrhosis)

24 weeks (with cirrhosis)

24 or 48 weeks

Daklanork is generally well tolerated with no known specific side-effects of its own.The most common side-effects seen in people taking Daklanork with Sofolanork are fatigue, nausea and headache. However, taking Daklanork with Interferon and Ribavirin can lead to additional side-effects including fever, muscle and joint aches, itching, depression, Anemia (low hemoglobin level) and Neutropenia (low white blood cell count).

Before taking Daklanork, tell your healthcare provider about all your medical conditions, if you have liver problems other than hepatitis C infection; have had a liver transplant; have heart problems; or if you are pregnant or breastfeeding or plan to become pregnant or breastfeed. It is not known if Daklanork will harm your unborn baby or pass into your breast milk.

Do not start taking a new medicine without telling your healthcare provider. Daklanork may affect the way other medicines work, and other medicines may affect how Daklanork works.